The PRESERVE Trial, which was recently published in the NEJM was a large study of a variety of preventive measures for contrast-induced nephropathy. It used a 2×2 factorial design to test the efficacy of NaHCO3 vs. normal saline…
A few months ago, a paper was published in the International Journal of Epidemiology that caused a sensation in it’s home country – Denmark. Using registry data, and the diagnosis of non-melanomatous skin cancer as a proxy for…
In NDT this month, there is a nice series of articles outlining the ongoing debate about whether or not an eGFR<60 should be considered a disease, particularly in the elderly. The pro side was argued by Giuseppe Conte…
Recommendation 3: The ACP recommends that clinicians select pharmacologic therapy that includes either an angiotensin-converting enzyme inhibitor (moderate-quality evidence) or an angiotensin II-receptor blocker (high-quality evidence) in patients with hypertension and stage 1 to 3 chronic kidney disease….
Recommendation 2: The ACP recommends against testing for proteinuria in adults with or without diabetes who are currently taking an angiotensin-converting enzyme inhibitor or an angiotensin II-receptor blocker. (Grade: weak recommendation, low quality evidence) This is an interesting…
A few days ago, I was asked to present the new ACP guidelines for screening for CKD stages 1-3 to a group of non-nephrologists. These guidelines were published online last October in Annals of Internal Medicine and provoked…
My attention was caught by the recent article in CJASN which compared the mortality of peritoneal dialysis (PD) and hemodialysis (HD) patients in the first 2 years of dialysis therapy. When comparing survival outcomes of PD and HD…
This month’s issue of NDT has an interesting debate concerning whether or not clinical laboratories should start reporting CKD-EPI GFR instead of MDRD. The pro side is here while the con side is here. Basically, the argument for…
Interesting paper this month in JAMA about post-marketing studies of adverse drug effects. Randomized controlled trials are obviously the gold standard for the detection of common adverse events related to treatment. The problem is that, if an adverse…
The above figure compares long term survival in a subgroup of a trial that was published in Circulation in 1980. This was a randomized controlled trial of just over 1000 patients with known cardiovascular disease who were treated with medical…
